Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: Evidence for original antigenic sin

mBio

Volumn 8, Issue 2, 2017, Pages

  Rajendran, Madhusudan ^a   Nachbagauer, Raffael ^a   Ermler, Megan E ^a   Bunduc, Paul ^a   Amanat, Fatima ^a   Izikson, Ruvim ^b   Cox, Manon ^b   Palese, Peter ^a   Eichelberger, Maryna ^c   Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Protein Sciences Corp   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Influenza; Influenza virus; Neuraminidase; Neuraminidase inhibition

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE; VIRUS ANTIBODY; NA PROTEIN, INFLUENZA A VIRUS; NA PROTEIN, INFLUENZA B VIRUS; VIRAL PROTEIN;

ADULT; AGE; AGED; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; INFLUENZA A VIRUS (H1N1); MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION; VIRUS ISOLATION; VIRUS STRAIN; ADOLESCENT; ADULT CHILD; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INFANT; MIDDLE AGED; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; ADULT CHILDREN; AGE FACTORS; AGED; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INFANT; MIDDLE AGED; NEURAMINIDASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRAL PROTEINS; YOUNG ADULT;

EID: 85019092832     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02281-16     Document Type: Article

References (46)

1. Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:167-182. https://doi.org/10.1038/ nrd4529.
2. Heaton NS, Sachs D, Chen CJ, Hai R, Palese P. 2013. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc Natl Acad Sci U S A 110:20248-20253. https://doi.org/10.1073/pnas.1320524110.
3. Wohlbold TJ, Krammer F. 2014. In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen. Viruses 6:2465-2494. https://doi.org/10.3390/v6062465.
4. Eichelberger MC, Wan H. 2015. Influenza neuraminidase as a vaccine antigen. Curr Top Microbiol Immunol 386:275-299. https://doi.org/10.1007/82_2014_398.
5. Johansson BE, Matthews JT, Kilbourne ED. 1998. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16: 1009-1015. https://doi.org/10.1016/S0264-410X(97)00279-X.
6. Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F. 2015. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, crossprotection against influenza virus infection in mice. m Bio 6:e02556-14. https://doi.org/10.1128/m Bio.02556-14.
7. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. 2015. Antibody to influenza virus neuraminidase: an independent correlate of protection. J Infect Dis 212:1191-1199. https:// doi.org/10.1093/infdis/jiv195.
8. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW, Ogra PL. 1987. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 138:3010-3013.
9. Johansson BE, Moran TM, Kilbourne ED. 1987. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci U S A 84:6869-6873. https://doi.org/10.1073/pnas.84.19.6869.
10. Johansson BE, Kilbourne ED. 1993. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 67:5721-5723.
11. Webster RG, Laver WG, Kilbourne ED. 1968. Reactions of antibodies with surface antigens of influenza virus. J Gen Virol 3:315-326. https://doi.org/10.1099/0022-1317-3-3-315.
12. Schulman JL, Khakpour M, Kilbourne ED. 1968. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2:778-786.
13. Johansson BE, Grajower B, Kilbourne ED. 1993. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 11:1037-1039. https://doi.org/10.1016/0264-410X(93)90130-P.
14. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED. 1974. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129:411-420. https://doi.org/10.1093/infdis/129.4.411.
15. Wohlbold TJ, Hirsh A, Krammer F. 2015. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13. Vaccine 33:1102-1106. https://doi.org/10.1016/j.vaccine.2015.01.026.
16. Wohlbold TJ, Chromikova V, Tan GS, Meade P, Amanat F, Comella P, Hirsh A, Krammer F. 2015. Hemagglutinin stalk-and neuraminidasespecific monoclonal antibodies protect against lethal H10N8 influenza virus infection in mice. J Virol 90:851-861. https://doi.org/10.1128/JVI.02275-15.
17. Wan H, Yang H, Shore DA, Garten RJ, Couzens L, Gao J, Jiang L, Carney PJ, Villanueva J, Stevens J, Eichelberger MC. 2015. Structural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers. Nat Commun 6:6114. https://doi.org/10.1038/ncomms7114.
18. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, Wan H, Eichelberger MC, Taubenberger JK. 2012. Protection against a lethal H5N1 influenza challenge by intranasal immunization with viruslike particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432:39-44. https://doi.org/10.1016/j.virol.2012.06.003.
19. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC. 2013. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87:9290-9300. https://doi.org/10.1128/JVI.01203-13.
20. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. 2015. Cross-reactive neuraminidase-inhibiting antibodies elicited by immunization with recombinant neuraminidase proteins of H5N1 and pandemic H1N1 influenza A viruses. J Virol 89:7224-7234. https://doi.org/10.1128/JVI.00585-15.
21. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLo S Med 4:e59. https://doi.org/10.1371/journal.pmed.0040059.
22. Jiang L, Fantoni G, Couzens L, Gao J, Plant E, Ye Z, Eichelberger MC, Wan H. 2015. Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. J Virol 90:117-128. https://doi.org/10.1128/JVI.01756-15.
23. Halbherr SJ, Ludersdorfer TH, Ricklin M, Locher S, Berger Rentsch M, Summerfield A, Zimmer G. 2015. Biological and protective properties of immune sera directed to influenza virus neuraminidase. J Virol 89: 1550-1563. https://doi.org/10.1128/JVI.02949-14.
24. Memoli MJ, Shaw PA, Han A, Czajkowski L, Reed S, Athota R, Bristol T, Fargis S, Risos K, Powers JH, Davey RT, Taubenberger JK. 2016. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A/H1N1 virus healthy human challenge model. m Bio 7:e00417-16. https://doi.org/10.1128/m Bio.00417-16.
25. Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R, Eichelberger M. 2014. An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods 210:7-14. https://doi.org/10.1016/j.jviromet.2014.09.003.
26. Gao J, Couzens L, Eichelberger MC. 2016. Measuring influenza neuraminidase inhibition antibody titers by enzyme-linked lectin assay. J Vis Exp 2016:54573. https://doi.org/10.3791/54573.
27. Fonville JM, Wilks SH, James SL, Fox A, Ventresca M, Aban M, Xue L, Jones TC, Le NM, Pham QT, Tran ND, Wong Y, Mosterin A, Katzelnick LC, Labonte D, Le TT, van der Net G, Skepner E, Russell CA, Kaplan TD, Rimmelzwaan GF, Masurel N, de Jong JC, Palache A, Beyer WE, Le QM, Nguyen TH, Wertheim HF, Hurt AC, Osterhaus AD, Barr IG, Fouchier RA, Horby PW, Smith DJ. 2014. Antibody landscapes after influenza virus infection or vaccination. Science 346:996-1000. https://doi.org/10.1126/ science.1256427.
28. Fazekas de StGroth WRG, Webster RG. 1966. Disquisitions on original antigenic sin. II. Proof in lower creatures. J Exp Med 124:347-361. https:// doi.org/10.1084/jem.124.3.347.
29. Fazekas de StGroth WRG, Webster RG. 1966. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 124:331-345. https://doi.org/10.1084/jem.124.3.331.
30. Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F. 2016. Age dependence and isotype specificity of influenza virus hemaggluti-nin stalk-reactive antibodies in humans. m Bio 7:e01996-15. https://doi.org/10.1128/m Bio.01996-15.
31. Pedersen GK, Höschler K, Øie Solbak SM, Bredholt G, Pathirana RD, Afsar A, Breakwell L, Nøstbakken JK, Raae AJ, Brokstad KA, Sjursen H, Zambon M, Cox RJ. 2014. Serum Ig G titres, but not avidity, correlates with neutralizing antibody response after H5N1 vaccination. Vaccine 32: 4550-4557. https://doi.org/10.1016/j.vaccine.2014.06.009.
32. Manenti A, Tete SM, Mohn KG, Jul-Larsen Å, Gianchecchi E, Montomoli E, Brokstad KA, Cox RJ. 2017. Comparative analysis of influenza A(H3N2) virus hemagglutinin specific Ig G subclass and Ig A responses in children and adults after influenza vaccination. Vaccine 35:191-198. https://doi.org/10.1016/j.vaccine.2016.10.024.
33. Kosik I, Yewdell JW. 2017. Influenza A virus hemagglutinin specific antibodies interfere with virion neuraminidase activity via two distinct mechanisms. Virology 500:178-183. https://doi.org/10.1016/j.virol.2016.10.024.
34. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH. 2012. Highly conserved protective epitopes on influenza B viruses. Science 337:1343-1348. https://doi.org/10.1126/science.1222908.
35. Heaton NS, Leyva-Grado VH, Tan GS, Eggink D, Hai R, Palese P. 2013. In vivo bioluminescent imaging of influenza A virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 87: 8272-8281. https://doi.org/10.1128/JVI.00969-13.
36. Desbien AL, Van Hoeven N, Reed SJ, Casey AC, Laurance JD, Baldwin SL, Duthie MS, Reed SG, Carter D. 2013. Development of a high density hemagglutinin protein microarray to determine the breadth of influenza antibody responses. Biotechniques 54:345-348. https://doi.org/10.2144/ 000114041.
37. Wang TT, Tan GS, Hai R, Pica N, Petersen E, Moran TM, Palese P. 2010. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLo S Pathog 6:e1000796. https://doi.org/10.1371/journal.ppat.1000796.
38. Tanimoto T, Nakatsu R, Fuke I, Ishikawa T, Ishibashi M, Yamanishi K, Takahashi M, Tamura S. 2005. Estimation of the neuraminidase content of influenza viruses and split-product vaccines by immunochromatography. Vaccine 23:4598-4609. https://doi.org/10.1016/j.vaccine.2005.04.042.
39. Mc Cullers JA, Hayden FG. 2012. Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis 205:870-872. https://doi.org/10.1093/infdis/jir865.
40. Tan GS, Lee PS, Hoffman RM, Mazel-Sanchez B, Krammer F, Leon PE, Ward AB, Wilson IA, Palese P. 2014. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol 88:13580-13592. https://doi.org/10.1128/JVI.02289-14.
41. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. 2010. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 45:226-234. https://doi.org/10.1007/s12033-010-9268-3.
42. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 81: e51112. https://doi.org/10.3791/51112.
43. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLo S One 7:e43603. https://doi.org/10.1371/journal.pone.0043603.
44. King JC, Cox MM, Reisinger K, Hedrick J, Graham I, Patriarca P. 2009. Evaluation of the safety, reactogenicity and immunogenicity of Flu Blok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months. Vaccine 27:6589-6594. https://doi.org/10.1016/j.vaccine.2009.08.032.
45. Treanor JJ, El Sahly H, King J, Graham I, Izikson R, Kohberger R, Patriarca P, Cox M. 2011. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (Flu Blok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 29:7733-7739. https://doi.org/10.1016/j.vaccine.2011.07.128.
46. Keitel WA, Treanor JJ, El Sahly HM, Gilbert A, Meyer AL, Patriarca PA, Cox MM. 2009. Comparative immunogenicity of recombinant influenza hemagglutinin (r HA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old. Vaccine 28:379-385. https://doi.org/10.1016/j.vaccine.2009.10.037.